scholarly journals Drug development strategies for the treatment of obesity: how to ensure efficacy, safety, and sustainable weight loss

2014 ◽  
pp. 2391 ◽  
Author(s):  
Luisa Seoane ◽  
Silvia Barja-Fenández ◽  
Rosaura Leis ◽  
Felipe F Casanueva
Keyword(s):  
Weight Loss ◽  
Drug Development ◽  
Development Strategies ◽  
Treatment Of Obesity

Liraglutide for the Treatment of Obesity: Analyzing Published Reviews

2019 ◽  
Vol 25 (15) ◽  
pp. 1783-1790 ◽  
Author(s):  
Rosario Pastor ◽  
Josep A. Tur
Keyword(s):  
Weight Loss ◽  
Clinical Trials ◽  
Systematic Reviews ◽  
Randomized Clinical Trials ◽  
Statistical Tests ◽  
Overweight And Obesity ◽  
Cochrane Library ◽  
Medical Subject Headings ◽  
Mesh Terms ◽  
Treatment Of Obesity

Background: Several drugs have been currently approved for the treatment of obesity. The pharmacokinetic of liraglutide, as well as the treatment of type 2 diabetes mellitus, have been widely described. Objective: To analyze the published systematic reviews on the use of liraglutide for the treatment of obesity. Methods: Systematic reviews were found out through MEDLINE searches, through EBSCO host and the Cochrane Library based on the following terms: "liraglutide" as major term and using the following Medical Subject Headings (MesH) terms: "obesity", "overweight", "weight loss". A total of 3 systematic reviews were finally included to be analyzed. Results: From the three systematic reviews selected, only two included the randomized clinical trials, while the third study reviewed both randomized and non-randomized clinical trials. Only one review performed statistical tests of heterogeneity and a meta-analysis, combining the results of individual studies. Another review showed the results of individual studies with odds ratio and confidence interval, but a second one just showed the means and confidence intervals. In all studies, weight loss was registered in persons treated with liraglutide in a dose dependent form, reaching a plateau at 3.0 mg dose, which was reached just in men. Most usual adverse events were gastrointestinal. Conclusion: More powerful and prospective studies are needed to assess all aspects related to liraglutide in the overweight and obesity treatment.

scholarly journals Group dynamics are associated with weight loss in the behavioral treatment of obesity

Obesity ◽  
2015 ◽  
Vol 23 (8) ◽  
pp. 1563-1569 ◽  
Author(s):  
Lisa M. Nackers ◽  
Pamela J. Dubyak ◽  
Xiaomin Lu ◽  
Stephen D. Anton ◽  
Gareth R. Dutton ◽  
...  
Keyword(s):  
Weight Loss ◽  
Group Dynamics ◽  
Behavioral Treatment ◽  
Treatment Of Obesity

scholarly journals Dietary energy density in the treatment of obesity: a year-long trial comparing 2 weight-loss diets

2007 ◽  
Vol 85 (6) ◽  
pp. 1465-1477 ◽  
Author(s):  
Julia A Ello-Martin ◽  
Liane S Roe ◽  
Jenny H Ledikwe ◽  
Amanda M Beach ◽  
Barbara J Rolls
Keyword(s):  
Weight Loss ◽  
Energy Density ◽  
Dietary Energy ◽  
Treatment Of Obesity ◽  
Dietary Energy Density

Infant Obesity, Weight Reduction with Normal Increase in Linear Growth and Fat-free Body Mass

PEDIATRICS ◽  
1992 ◽  
Vol 89 (1) ◽  
pp. 143-145
Author(s):  
JOYCE M. PEIPERT ◽  
VIRGINIA A. STALLINGS ◽  
GERARD T. BERRY ◽  
JULE ANNE D. HENSTENBURG
Keyword(s):  
Weight Loss ◽  
Body Mass ◽  
Weight Maintenance ◽  
Caloric Intake ◽  
Resting Energy Expenditure ◽  
Induce Weight Loss ◽  
Infant Obesity ◽  
Normal Increase ◽  
Free Body ◽  
Treatment Of Obesity

Dietary caloric restriction, as a means to induce weight loss, is seldom used as a treatment of obesity in infancy for fear that permanent stunting of growth may result.1-4 Thus, there is little information on controlled weight loss as the treatment for infant obesity or, more importantly, its effect on growth in length, head circumference, and fat-free body mass during weight loss.5 We present a case of an obese infant who, secondary to a metabolic disorder, required nutritional support both intravenously and by nasogastric tube. During 15 months, the patient's resting energy expenditure (REE) was measured to determine an appropriate caloric intake to promote weight loss and later weight maintenance.

scholarly journals α-Methyl-L-Tryptophan as a Weight-Loss Agent in Multiple Models of Obesity in Mice

2021 ◽  
Author(s):  
Sathish Sivaprakasam ◽  
Sabarish Ramachandran ◽  
Mohd Omar Faruk Sikder ◽  
Yangzom Doma Bhutia ◽  
Mitchell Wachtel ◽  
...  
Keyword(s):  
Weight Loss ◽  
High Fat Diet ◽  
Amino Acid Profile ◽  
Normal Diet ◽  
The Body ◽  
Multiple Models ◽  
High Fat ◽  
Liver And Kidney ◽  
Obesity In Mice ◽  
Treatment Of Obesity

a-Methyl-L-tryptophan (a-MLT) is currently in use as a tracer in its 11C-labeled form to monitor the health of serotonergic neurons in humans. In the present study, we found this compound to function as an effective weight-loss agent at pharmacological doses in multiple models of obesity in mice. The drug was able to reduce the body weight when given orally in drinking water (1 mg/ml) in three different models of obesity: normal mice on high-fat diet, Slc6a14-null mice on high-fat diet, and ob/ob mice on normal diet. Only the L-enantiomer (a-MLT) was active while the D-enantiomer (a-MDT) had negligible activity. The weight-loss effect was freely reversible, with the weight gain resuming soon after the withdrawal of the drug. All three models of obesity were associated with hyperglycemia, insulin resistance, and hepatic steatosis; a-MLT reversed these features. There was a decrease in food intake in the treatment group. Mice on a high-fat diet showed decreased cholesterol and protein in the serum when treated with a-MLT; there was however no evidence of liver and kidney dysfunction. Plasma amino acid profile indicated a significant decrease in the levels of specific amino acids, including tryptophan; but the levels of arginine were increased. We conclude that a-MLT is an effective, reversible, and orally active drug for the treatment of obesity and metabolic syndrome.

scholarly journals Mangosteen Shows a Potent Insulin Sensitizing Effect in Obese Female Patients: A Prospective Randomized Controlled Pilot Study

2018 ◽  
Author(s):  
Mikiko Watanabe ◽  
Elena Gangitano ◽  
Davide Francomano ◽  
Eliana Addessi ◽  
Raffaella Toscano ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Weight Loss ◽  
Pilot Study ◽  
Behavioral Therapy ◽  
Antioxidant Properties ◽  
Model Assessment ◽  
Female Patients ◽  
Inflammatory Status ◽  
Obese Female ◽  
Treatment Of Obesity

Insulin resistance is the most important underlying cause of obesity and type 2 Diabetes (T2DM), and insulin sensitizing treatments have proved effective in preventing diabetes and inducing weight loss. Obesity and T2DM are also associated with increased inflammation. Mangosteen is a tropical tree, whose fruits, widely known for their antioxidant properties, have been recently suggested having a possible further role in the treatment of obesity and T2DM. The objective of this pilot study has been to evaluate safety, compliance and efficacy of mangosteen on insulin resistance, weight management, and inflammatory status in obese female patients with insulin resistance. 22 patients were randomized 1:1 to behavioral therapy alone or behavioral therapy and mangosteen and 20 completed the 26-week study. The mangosteen group reported a significant improvement in insulin sensitivity (HOmeostatic Model Assessment-Insulin Resistance, HOMA-IR -53.22% vs -15.23%, p=.0037), and a trend decrease in inflammation markers serum levels, together with trend greater weight loss and trend increased HDL levels. No side effect attributable to treatment was reported. Given the positive preliminary results we report and the excellent safety profile, we suggest a possible role of mangosteen in the treatment of obesity, insulin resistance and inflammation.

Endoscopic Approaches to Obesity Management

2021 ◽  
Vol 73 (1) ◽  
Author(s):  
Russell D. Dolan ◽  
Allison R. Schulman
Keyword(s):  
Metabolic Disease ◽  
Weight Loss ◽  
Small Bowel ◽  
Weight Regain ◽  
Caloric Intake ◽  
Annual Review ◽  
Publication Date ◽  
Obesity Management ◽  
Surgical Interventions ◽  
Treatment Of Obesity

The field of endoscopic bariatric and metabolic therapy has rapidly evolved from offering endoscopic treatment of weight regain following bariatric surgery to providing primary weight loss options as alternatives to pharmacologic and surgical interventions. Gastric devices and remodeling procedures were initially designed to work through a mechanism of volume restriction, leading to earlier satiety and reduced caloric intake. As the field continues to grow, small bowel interventions are evolving that may have some effect on weight loss but focus on the treatment of obesity-related comorbidities. Future implementation of combination therapy that utilizes both gastric and small bowel interventions offers an exciting option to further augment weight loss and alleviate metabolic disease. This review considers gastric devices and techniques including space-occupying intragastric balloons, aspiration therapy, endoscopic tissue suturing, and plication interventions, followed by a review of small bowel interventions including endoluminal bypass liners, duodenal mucosal resurfacing, and endoscopically delivered devices to create incisionless anastomoses. Expected final online publication date for the Annual Review of Medicine, Volume 73 is January 2022. Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates.

Sign in / Sign up

Export Citation Format

Share Document